AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Klotho

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9UEF7

UPID:

KLOT_HUMAN

Alternative names:

-

Alternative UPACC:

Q9UEF7; Q5VZ95; Q96KV5; Q96KW5; Q9UEI9; Q9Y4F0

Background:

Klotho, identified by its gene symbol Q9UEF7, plays a pivotal role in calcium and phosphorus homeostasis, potentially through its involvement in the regulation of vitamin D synthesis. It exhibits a unique function by facilitating the specific interaction between FGF23 and FGFR1, crucial for mineral metabolism. Additionally, Klotho may possess glycosidase activity towards glucuronylated steroids, despite lacking key active site residues, suggesting a non-enzymatic role in vivo.

Therapeutic significance:

Klotho's association with Tumoral calcinosis, hyperphosphatemic, familial, 3, underscores its therapeutic potential. This rare metabolic disorder, characterized by hyperphosphatemia and calcium deposits, highlights the protein's significance in mineral metabolism disorders. Understanding Klotho's role could pave the way for innovative treatments targeting calcium and phosphorus homeostasis.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.